Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

资源控股
RESOURCES HOLDINGS

Peking University Resources (Holdings) Company Limited
北大資源(控股)有限公司

(Incorporated in Bermuda with limited liability)

(Stock code: 00618)

VOLUNTARY ANNOUNCEMENT
ESTABLISH OF AI HEALTHCARE SERVICES ADVISORY BOARD

This announcement is made by Peking University Resources (Holdings) Company Limited (the "**Company**", and together with its subsidiaries, the "**Group**") on a voluntary basis.

Establish AI Healthcare Services Advisory Board to Support the Development of LetsGo Platform Across Emerging Markets

The Company is pleased to announce the establishment of an AI Healthcare Services Advisory Board (the "**Advisory Board**") to provide strategic guidance and expert insight to the board of directors of the Company (the "**Board**") on the development of the Group's AI-powered digital health platform, LetsGo, under the Company's subsidiary Hong Kong Fuhe Holdings Limited, and its healthcare innovation arm, Resohealth FZCO ("**ResoHealth**").

This initiative reflects the Group's commitment to building a scalable and ethical preventive health ecosystem across key emerging markets, including the United Arab Emirates (UAE), East Africa, India, and Southeast Asia.

Introduction of LetsGo and ResoHealth

LetsGo is ResoHealth's flagship AI health platform, designed to provide integrated, data-driven health management solutions to employers, insurers, and healthcare institutions. Built on the preventive care philosophy of the 400-year-old Chinese brand **"葉開泰"**, LetsGo combines traditional medical wisdom with modern AI technologies to address global health challenges at scale.

The platform operates around four key pillars:

- AI-powered health screening
- Personalized intervention and coaching
- Insurance optimization and cost savings
- Health data management and ecosystem integration

Purpose of the Advisory Board

The Advisory Board is a non-statutory, consultative body established on a voluntary basis. It is independent from the formal Board committees required under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and holds no executive or voting authority.

Its primary function is to advise the Board on strategic, technical, and operational matters related to the development and deployment of the LetsGo platform, particularly in emerging markets.

Functions of the Advisory Board

The Advisory Board will focus on the following:

1. **Strategic Guidance**: Advise on the development roadmap and expansion strategy of LetsGo in the UAE, East Africa, India, and Southeast Asia.

2. **Technology and Investment Insight**: Provide expert perspectives on digital health innovation, responsible AI adoption, and healthcare investment trends.

3. **Operational Oversight Support**: Recommend best practices for market localization, ecosystem partnerships, and platform implementation.

4. **Ethical and Regulatory Considerations**: Advise on ethical standards, data privacy, and regulatory compliance across jurisdictions.

5. **Board Liaison**: Serve as a source of high-level insight to the Board through periodic briefings and written recommendations.

Structure and Governance

Members of the Advisory Board will be appointed by the Board and will include independent professionals from fields such as artificial intelligence, healthcare delivery, digital platforms, and health insurance. The Advisory Board will meet periodically and operate under a formal charter, with reporting lines to the Board via designated liaison directors.

This Advisory Board reinforces the Company's focus on innovation, cross-border health partnerships, and ethical technology development, ensuring that LetsGo evolves into a trusted platform for preventive healthcare across the regions it serves.

Members of the Advisory Board

Professor Richard Siow

Prof Richard Siow is a graduate of King's College London (BSc, PhD). Following his research fellowship in the Department of Medicine, University of Cambridge, since 2002 he has been a Principal Investigator at King's in the School of Cardiovascular and Metabolic Medicine, British Heart Foundation Centre of Research Excellence, undertaking research in nutrigenomics, cardiovascular and brain ageing.

Prof Siow was previously Vice-Dean (International), King's Faculty of Life Sciences & Medicine and is currently Director of Ageing Research at King's (ARK), a multidisciplinary consortium for healthy ageing, longevity and preventive medicine research.

Prof Siow also holds a Visiting Professorship in the Medical Sciences Division, University of Oxford, and is the Secretary General of the European Society for Preventive Medicine. He was a visiting academic in the Healthy Longevity Centre at University of Zurich, Switzerland and a research advisor at Unilever's global R&D centres.

Prof Siow is the Editor-in-Chief of Longevity, a Taylor & Francis journal and a member of the International Advisory Board of The Lancet Healthy Longevity. He was previously Chief Editor of Frontiers in Ageing (Healthy Longevity), Associate Editor of Frontiers in Nutrition, and a Strategic Advisory Board member of the UK All Party Parliamentary Group for Longevity. He is a Fellow of the Royal Society of Biology, European Society for Preventive Medicine and UK Lead for the International Society on Ageing & Disease.

Dr. GSK Velu

Dr. Velu positioned India on the world healthcare map by providing quality medical technology across the globe. He founded Trivitron Healthcare ("**Trivitron**") in 1997. Trivitron now stands as a largest medical technology company of Indian origin catering over 20 medical specialties across the globe.

Dr. Velu also established the Trivitron Medical Technology Park, South Asia's first state-of – the-art medical technology manufacturing facility. Apart from manufacturing, Trivitron strategically joined hands with many international universities for a broad scientific cooperation, and to raise the bars in the Research & Development for new technology developments.

Dr. Velu is the Chairman of Neuberg Diagnostics ("**Neuberg**"), a global pathology brand, operating in India, UAE, USA, Sri Lanka, South Africa.

Dr. Velu has investments in several hospitals across India, including the Kauvery Group of Hospitals, Chain of Multi-Specialty Hospitals with presence in 6 cities, 9 Hospitals and more than 1500 beds. The other notable hospital group is Maxivision Eye Hospitals, National chain of Eye care super specialty Hospitals. He is also an anchor investor at Stakeboat Capital, private equity fund and GSK Ventures. Stakeboat is a value oriented, alternative investment firm, focused on small and medium companies in select regions.

Dr. Velu is Honorary Consul to the Republic of Estonia in India (Honorary Consul jurisdiction states – Tamil Nadu, Kerala, Andhra Pradesh and Telangana).

Dr. Vasanthan Metupalle

Dr. Vasanthan Metupalle is a medical doctor, trained and a Singaporean healthcare entrepreneur with over 16 years of leadership across Asia, the Middle East, and Africa. He studied medicine at Guy's, King's and St. Thomas' School of Medicine (London), interned at Johns Hopkins Hospital in the US, and trained in radiology program at Singapore General Hospital. He also holds an MBA from Nanyang Business School (Singapore).

Dr. Vasanthan developed teleradiology platform Clarity Radiology in 2008, and co-founded MyDoc, the first telehealth platform in Asia in 2012. This platform received government commendation and Dr. Vasanthan personally was given the Public Service Medal, Singapore (2023), which was awarded by the Singapore Prime Minister's Office for contribution during the COVID-19 pandemic. After exiting MyDoc through an acquisition, he has setup and developed a multinational healthcare consulting platform company supporting digital transformation and cross-border medtech growth, with operations based in Dubai.

Dr. Vasanthan has operated in over 10 countries across Asia, including Vietnam, Thailand, the Philippines, and Indonesia, where he led expansion and distribution of diagnostic medical technology, telehealth solutions, and corporate health services.

Dr. Henry Loh

Dr. Henry Loh graduated from the University of Melbourne, Australia, and subsequently trained as a medical doctor and dermatologist at several prestigious institutions, including Guy's & St Thomas' Hospital in London, the National University Hospital, and the National Skin Centre in Singapore.

After completing his specialist training, Dr. Loh entered private practice and went on to establish a successful chain of dermatology clinics in Singapore, which was listed on the Stock Exchange of Hong Kong Limited in 2017.

Beyond clinical practice, Dr. Loh is a serial investor in medical technology and biotechnology ventures, with notable investments in companies such as ManaDr (Singapore), which was successfully listed on NASDAQ in 2023.

A strong advocate for innovation in healthcare, Dr. Loh believes that artificial intelligence will fundamentally transform the industry, evolving it from a labor-intensive service model into a scalable, data-driven product ecosystem. He also envisions the subscription-based model, emphasizing preventive care and early disease detection, as the future of modern medicine.

By order of the Board
Peking University Resources (Holdings) Company Limited
Wong Kai Ho
Chairman of the Board

Hong Kong, 21 November 2025

As at the date of this announcement, the Board comprises executive Directors of Mr. Wong Kai Ho (Chairman), Mr. Huang Zhuguang, Mr. Hou Ruilin and Mr. Xia Ding; and the independent non-executive Directors of Mr. Chin Chi Ho, Stanley, Ms. Xu Nan and Prof. Cheung Ka Yue.